- Report
- May 2022
- 58 Pages
Global
From €1987EUR$2,000USD£1,652GBP
- Report
- April 2022
- 50 Pages
Global
From €1987EUR$2,000USD£1,652GBP
- Report
- April 2022
- 632 Pages
Global
From €2484EUR$2,500USD£2,065GBP
- Report
- April 2022
- 37 Pages
Global
From €1987EUR$2,000USD£1,652GBP
- Report
- November 2024
Europe
From €2081EUR$2,095USD£1,730GBP
€3964EUR$3,990USD£3,296GBP
- Report
- November 2024
Global
From €2081EUR$2,095USD£1,730GBP
€3964EUR$3,990USD£3,296GBP
- Report
- November 2024
North America
From €2081EUR$2,095USD£1,730GBP
€3964EUR$3,990USD£3,296GBP
- Report
- November 2024
Europe
From €2081EUR$2,095USD£1,730GBP
€3964EUR$3,990USD£3,296GBP
- Report
- November 2024
Europe
From €2081EUR$2,095USD£1,730GBP
€3964EUR$3,990USD£3,296GBP
- Report
- November 2024
Europe
From €2081EUR$2,095USD£1,730GBP
€3964EUR$3,990USD£3,296GBP
- Report
- November 2024
China
From €2081EUR$2,095USD£1,730GBP
€3964EUR$3,990USD£3,296GBP
- Report
- November 2024
United States
From €2081EUR$2,095USD£1,730GBP
€3964EUR$3,990USD£3,296GBP
- Report
- November 2024
United Kingdom
From €2081EUR$2,095USD£1,730GBP
€3964EUR$3,990USD£3,296GBP
- Report
- November 2024
North America
From €2081EUR$2,095USD£1,730GBP
€3964EUR$3,990USD£3,296GBP
- Report
- November 2024
Europe
From €2081EUR$2,095USD£1,730GBP
€3964EUR$3,990USD£3,296GBP
- Report
- November 2024
Middle East
From €2081EUR$2,095USD£1,730GBP
€3964EUR$3,990USD£3,296GBP
- Report
- November 2024
Asia Pacific
From €2081EUR$2,095USD£1,730GBP
€3964EUR$3,990USD£3,296GBP
- Report
- November 2024
Global
From €2081EUR$2,095USD£1,730GBP
€3964EUR$3,990USD£3,296GBP
- Report
- November 2024
China
From €2081EUR$2,095USD£1,730GBP
€3964EUR$3,990USD£3,296GBP
- Report
- November 2024
United States
From €2081EUR$2,095USD£1,730GBP
€3964EUR$3,990USD£3,296GBP
The Gastrointestinal Drugs market is a sector of the pharmaceutical industry that focuses on the development and production of drugs used to treat diseases and disorders of the gastrointestinal tract. These drugs are used to treat conditions such as irritable bowel syndrome, Crohn's disease, ulcerative colitis, and gastroesophageal reflux disease. Commonly prescribed drugs include antacids, proton pump inhibitors, and H2 receptor antagonists.
The Gastrointestinal Drugs market is highly competitive, with many large pharmaceutical companies vying for market share. Some of the major players in the market include Pfizer, GlaxoSmithKline, Merck & Co., AstraZeneca, and Novartis. These companies are constantly developing new drugs and treatments to meet the needs of patients. Show Less Read more